KR102613901B1 - Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof - Google Patents
Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof Download PDFInfo
- Publication number
- KR102613901B1 KR102613901B1 KR1020210026764A KR20210026764A KR102613901B1 KR 102613901 B1 KR102613901 B1 KR 102613901B1 KR 1020210026764 A KR1020210026764 A KR 1020210026764A KR 20210026764 A KR20210026764 A KR 20210026764A KR 102613901 B1 KR102613901 B1 KR 102613901B1
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- extract
- present
- fraction
- composition
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 56
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 244000079489 Rorippa palustris Species 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 6
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 210000004153 islets of langerhan Anatomy 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000252212 Danio rerio Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007332 Podocarpus macrophyllus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000005809 Prunus persica Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000011331 Brassica Nutrition 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000011096 Papaver Nutrition 0.000 description 2
- 240000001090 Papaver somniferum Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241001343702 Anemia adiantifolia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Abstract
본 발명은 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물, 식품 조성물, 건강기능식품 조성물 및 상기 약학적 조성물을 투여하는 단계를 포함하는 당뇨병 치료 방법에 관한 것이다.
본 발명의 속속이풀 추출물 또는 이의 분획물을 포함하는 조성물은 고혈당 또는 당뇨병의 주요 증상을 감소시키면서도 경구 투여가 가능한 바, 당뇨병의 예방 또는 치료에 널리 활용될 수 있을 것이다.The present invention relates to a pharmaceutical composition, a food composition, a health functional food composition for the prevention or treatment of diabetes containing an extract or a fraction thereof as an active ingredient, and a method for treating diabetes comprising the step of administering the pharmaceutical composition. will be.
The composition containing the extract or fractions thereof of the present invention can be administered orally while reducing the main symptoms of hyperglycemia or diabetes, so it can be widely used in the prevention or treatment of diabetes.
Description
본 발명은 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물, 식품 조성물, 건강기능식품 조성물 및 상기 약학적 조성물을 투여하는 단계를 포함하는 당뇨병 치료 방법에 관한 것이다.The present invention relates to a pharmaceutical composition, a food composition, a health functional food composition for the prevention or treatment of diabetes containing an extract or a fraction thereof as an active ingredient, and a method for treating diabetes comprising the step of administering the pharmaceutical composition. will be.
당뇨병(糖尿病, diabetes mellitus)은 대표적인 만성 대사성 질환으로 인슐린의 비정상적 작용으로 인한 혈당치의 증가로 소변으로 당을 배출하는 질환이다. 당뇨병은 발생기전에 따라 제1형 당뇨병(인슐린 의존형 당뇨병)과 제2형 당뇨병(인슐린 비의존형 당뇨병)으로 분류하고 있으며, 그 중 제2형 당뇨병이 전체 당뇨병 환자의 약 95% 이상을 차지한다. 제1형 당뇨병은 췌장 베타세포를 파괴하는 자가면역과정이 주 원인으로, 인슐린의 분비 부족 또는 완전한 결핍이 특징이다. 제2형 당뇨병은 인슐린 저항성, 베타세포 기능 저하, 유전적 소인 등의 상호작용으로 발생한다. 인슐린 저항성을 극복하기 위하여 인슐린 분비가 증가하다가 어느 한도를 넘으면 더 이상 증가하지 못하여 혈당이 높아지고 당뇨병으로 발전하게 된다. 현재 제1형 및 제2형 당뇨병 환자에게 사용되는 경구혈당강하제로 α-glucosidase 억제제와 sulfonylurea 제제 및 dipeptidyl-peptidase 4 (DPP4) 억제제 등이 있다. 구체적으로, 소장에서 탄수화물의 흡수를 지연시켜 식후 혈당치가 급격히 상승하는 것을 막아주는 α-glucosidase 억제제와, 췌장의 베타세포에서 인슐린 분비를 촉진시키는 sulfonylurea 등이 있다. 또한, 인슐린의 분비를 촉진하고 혈당을 떨어뜨리는 역할을 하는 인크레틴 효소를 바로 분해하는 DPP4 효소를 선택적으로 저해하여, 인크레틴 효소가 장시간 높은 농도로 유지되도록 하는 DPP4 저해제가 있다. 임상에서 사용되고 있는 α-glucosidase 저해제 등의 당뇨병 치료제는 장기 복용할 경우 일부 환자에 있어서 복부 팽만감, 구토, 설사 등의 부작용을 나타낼 수 있어 그 사용이 제한될 수 있다. 현재까지 당뇨병의 완치법은 확립되어 있지 않고, 약물 치료의 부작용 때문에 약물 사용에 제한이 많아, 천연물로부터 당뇨병 치료제를 탐색하려는 연구가 활발히 진행되고 있다.Diabetes mellitus is a representative chronic metabolic disease in which sugar is excreted through urine due to an increase in blood sugar levels due to the abnormal action of insulin. Diabetes is classified into type 1 diabetes (insulin-dependent diabetes) and type 2 diabetes (non-insulin-dependent diabetes) depending on the mechanism of development, of which type 2 diabetes accounts for more than 95% of all diabetes patients. Type 1 diabetes is mainly caused by an autoimmune process that destroys pancreatic beta cells and is characterized by insufficient secretion or complete deficiency of insulin. Type 2 diabetes occurs due to the interaction of insulin resistance, decreased beta cell function, and genetic predisposition. To overcome insulin resistance, insulin secretion increases, but when it exceeds a certain limit, it can no longer increase, causing blood sugar levels to rise and developing diabetes. Currently, oral hypoglycemic agents used in patients with type 1 and type 2 diabetes include α-glucosidase inhibitors, sulfonylurea agents, and dipeptidyl-peptidase 4 (DPP4) inhibitors. Specifically, there are α-glucosidase inhibitors, which delay the absorption of carbohydrates in the small intestine and prevent a rapid rise in blood sugar levels after a meal, and sulfonylureas, which promote insulin secretion from pancreatic beta cells. In addition, there is a DPP4 inhibitor that selectively inhibits the DPP4 enzyme, which directly decomposes the incretin enzyme, which promotes the secretion of insulin and lowers blood sugar levels, allowing the incretin enzyme to be maintained at a high concentration for a long time. Diabetes treatments such as α-glucosidase inhibitors used clinically may cause side effects such as abdominal distension, vomiting, and diarrhea in some patients when taken for a long period of time, which may limit their use. To date, a cure for diabetes has not been established, and there are many restrictions on the use of drugs due to the side effects of drug treatment, so research is actively underway to explore diabetes treatments from natural products.
한편, 속속이풀(Rorippa palustris)은 한국 및 북반구의 온대에 분포하는 양귀비목 십자화과의 식물이다. 논두렁, 냇가 등 낮은 지대의 습기가 있는 곳에서 자생하며, 5-7월에 개화한다. 속속이풀은 어린순을 나물로 식용하며, 한방에서 황달, 혈액순환촉진, 해독 등의 약재로 사용하였으나, 속속이풀의 당뇨 치료 효능에 대해서는 전혀 연구된 바 없다.Meanwhile, Rorippa palustris is a plant of the Papaver order Brassica family distributed in temperate regions of Korea and the northern hemisphere. It grows wild in moist places in low areas such as rice paddies and streams, and blooms from May to July. The young shoots of the plant are edible as a vegetable, and it is used as a medicine in oriental medicine to treat jaundice, promote blood circulation, and detoxify, but there has been no research on the efficacy of the plant in treating diabetes.
이러한 배경 하에서, 본 발명자들은 합성 약물보다 안전성이 있는 천연물을 이용하여 당뇨병을 개선 및 치료하는 방법을 개발하고자 예의 연구 노력한 결과, 속속이풀 추출물이 당뇨병을 치료하는 효과를 나타냄을 확인함으로써 본 발명을 완성하였다.Under this background, the present inventors have made extensive research efforts to develop a method for improving and treating diabetes using natural products that are safer than synthetic drugs, and as a result, it has been confirmed that the extract of Sulfuria chinensis exhibits an effect in treating diabetes, thereby establishing the present invention. Completed.
본 발명의 목적은 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.The purpose of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diabetes containing an extract or a fraction thereof as an active ingredient.
본 발명의 다른 하나의 목적은 상기 약학적 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 당뇨병의 치료 방법을 제공하는 것이다.Another object of the present invention is to provide a method for treating diabetes, comprising administering the pharmaceutical composition to an individual in need thereof.
본 발명의 또 다른 하나의 목적은 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or ameliorating diabetes, comprising an extract or a fraction thereof as an active ingredient.
본 발명의 또 다른 하나의 목적은 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for preventing or improving diabetes, which contains an extract or a fraction thereof as an active ingredient.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Additionally, the scope of the present invention cannot be considered limited by the specific description described below.
또한, 당해 기술분야의 통상의 지식을 가진 자는 통상의 실험만을 사용하여 본 발명에 기재된 본 발명의 특정 양태에 대한 다수의 등가물을 인지하거나 확인할 수 있다. 또한, 이러한 등가물은 본 발명에 포함되는 것으로 의도된다.Additionally, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Additionally, such equivalents are intended to be encompassed by this invention.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물을 제공한다.One aspect of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of diabetes, comprising an extract or a fraction thereof as an active ingredient.
본 발명의 "속속이풀(Rorippa palustris)"은 양귀비목 십자화과의 두해살이 또는 다년생 식물로서, 풍화채라고도 불린다. 속속이풀은 온대와 난대에 걸쳐 분포하며, 한방에서 이뇨, 혈액순환, 해독 등에 처방하여 사용되었다. 그러나, 속속이풀의 당뇨 치료 효능에 대해서는 연구된 바 없다. 이에, 본 발명에서는 속속이풀 추출물이 당뇨병의 치료 효과가 있음을 최초로 규명하였다." Rorippa palustris " of the present invention is a biennial or perennial plant of the Papaver order Brassica family, and is also called weathered vegetable. It is distributed throughout the temperate and subtropical zones, and is used in oriental medicine for diuresis, blood circulation, and detoxification. However, there has been no research on the diabetes treatment efficacy of Sulfuria chinensis. Accordingly, in the present invention, it was discovered for the first time that the extract of Siberia chinensis has a therapeutic effect on diabetes.
본 발명의 속속이풀 추출물은 속속이풀의 지상부, 구체적으로, 줄기, 잎 등을 추출한 것일 수 있고, 또는 이들의 부위를 혼합하여 추출한 것일 수 있으나, 이에 제한되지 않는다.The Herbaceae extract of the present invention may be extracted from the aerial parts of Herbaceae, specifically, stems, leaves, etc., or may be extracted by mixing these parts, but is not limited thereto.
본 발명의 속속이풀은 원물, 건조물 또는 가공물일 수 있으며, 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것, 또는 기탁 기관 등에서 분양 받은 것 등을 추출물 제조에 사용할 수 있으나, 이에 제한되지 않는다. The herbaceous herb of the present invention may be raw, dried, or processed, and may be purchased and used commercially, collected or cultivated in nature, or distributed from a depository organization, etc., may be used to manufacture extracts. It is not limited to this.
본 발명의 용어 "추출물"이란, 목적하는 물질을 다양한 용매에 침지한 다음, 상온 또는 가온 상태에서 일정 시간 동안 추출하여 수득한 액상 성분, 상기 액상 성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미한다. 뿐만 아니라, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다. 이에 따라, 본 발명에서 제공하는 속속이풀 추출물은 속속이풀을 추출하여 얻어지는 추출액, 상기 추출액을 효소 분해하여 얻어지는 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함하는 것으로 해석될 수 있다.The term "extract" in the present invention refers to the resulting liquid component obtained by immersing the target material in various solvents and then extracting it at room temperature or at a heated state for a certain period of time, and the solid content obtained by removing the solvent from the liquid component. it means. In addition, it can be comprehensively interpreted to include all diluted solutions of the above results, concentrated solutions thereof, crude products, purified products, etc. Accordingly, the extract provided by the present invention is the extract itself and all formulations that can be formed using the extract, such as an extract obtained by extracting the extract, a purified product obtained by enzymatically decomposing the extract, or a mixture thereof. It can be interpreted as including the extract.
본 발명의 속속이풀을 추출하는 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The method for extracting the herbaceous herb of the present invention is not particularly limited, and can be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, which may be performed alone or by combining two or more methods.
본 발명에서 상기 추출에 사용되는 용매의 종류는 특별히 제한되지 않으며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물, 알코올 또는 이들의 혼합 용매 등을 들 수 있고, 이들은 단독으로 사용되거나 2종 이상 혼합하여 사용될 수 있으며, 알코올을 용매로 사용하는 경우에는 구체적으로 탄소수 1 내지 4의 알코올을 사용할 수 있다. 구체적으로, 70% 에탄올을 사용하는 것일 수 있으나, 이에 제한되지 않는다.In the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, alcohol, or a mixed solvent thereof, and these may be used alone or in a mixture of two or more types. When alcohol is used as a solvent, specifically, the extraction solvent may have 1 to 1 carbon atoms. 4 alcohol can be used. Specifically, 70% ethanol may be used, but is not limited thereto.
본 발명의 용어 "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.The term “fraction” in the present invention refers to the result obtained by performing fractionation to separate a specific component or specific group of components from a mixture containing various components.
본 발명에서 상기 분획물을 얻는 분획 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 수행될 수 있다. 상기 분획 방법의 비제한적인 예로는, 다양한 용매를 처리하여 수행하는 분획법, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 수행하는 한외여과 분획법, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)를 수행하는 크로마토그래피 분획법, 및 이들의 조합 등이 있다. 구체적으로, 본 발명의 속속이풀을 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법을 들 수 있다.In the present invention, the fractionation method for obtaining the fraction is not particularly limited and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include fractionation performed by treating various solvents, ultrafiltration fractionation performed by passing through an ultrafiltration membrane with a certain molecular weight cut-off value, and various chromatography methods (size, charge, hydrophobicity or There are chromatographic fractionation methods (designed for separation based on affinity), and combinations thereof. Specifically, a method of obtaining a fraction from the extract of the present invention by treating the extract obtained by extracting the herbaceous herbacea with a predetermined solvent is included.
본 발명에서 상기 분획물을 얻는 데 사용되는 분획 용매의 종류는 특별히 제한되지 않으며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매의 비제한적인 예로는 물, 탄소수 1 내지 4의 알코올 등의 극성 용매; 헥산(Hexan), 에틸 아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매; 또는 이들의 혼합용매 등을 들 수 있다. 이들은 단독으로 사용되거나 1종 이상 혼합하여 사용될 수 있지만, 이에 제한되는 것은 아니며, 구체적으로, 헥산, 에틸 아세테이트, 부탄올(butanol) 또는 물이 단독으로 사용되거나 1종 이상 혼합하여 사용될 수 있지만, 이에 제한되는 것은 아니다.The type of fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionating solvent include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Non-polar solvents such as hexan, ethyl acetate, chloroform, and dichloromethane; Or a mixed solvent thereof, etc. may be mentioned. These may be used alone or in a mixture of one or more types, but are not limited thereto. Specifically, hexane, ethyl acetate, butanol, or water may be used alone or in a mixture of one or more types, but are limited thereto. It doesn't work.
또한, 상기 추출물 또는 분획물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있지만, 이제 제한되는 것은 아니다.Additionally, the extract or fraction may be prepared and used in the form of a dry powder after extraction, but this is not limited.
본 발명의 "당뇨병(diabetes)"은 인슐린의 분비량이 부족하거나 인슐린의 작용 및 기능이 충분히 이루어지지 않을 때 나타나는 질병을 의미한다. 구체적으로, 글리코겐, 단백질 및 지방질의 과도한 분해로 간 또는 혈액 중의 글루코스 농도의 비정상적인 증가를 일으켜 당뇨 및 케톤뇨를 초래하고, 수분 및 전해질 대사의 이상으로 전해실 상실에 의한 혈액 농축 상태와 함께 순환 장애, 신장 장애 등의 병적 상태를 가져오게 된다. 인슐린은 췌장 내에 존재하는 췌장섬의 β-세포에서 혈중 글루코스 농도가 증가하면 분비되고, 감소하면 분비가 억제되어 에너지원의 적절한 활동을 조절하게 된다. 당뇨병 진단은 일반적으로 혈중 글루코스 농도의 측정을 통해서 가능한데, 인간에게서는 일반적으로 혈중 글루코스가 평소 200 mg/dl 이상, 공복 시 140 mg/dl 이상일 때 당뇨병으로 진단한다. 따라서, 손상된 췌장 β-세포를 회복시키거나 췌장섬 세포 내 글루코스 흡수를 증가시켜 당뇨병의 치료 또는 예방 용도에 유용하게 사용될 수 있다.“Diabetes” in the present invention refers to a disease that occurs when the secretion of insulin is insufficient or the action and function of insulin are not sufficiently achieved. Specifically, excessive decomposition of glycogen, proteins and lipids causes an abnormal increase in the concentration of glucose in the liver or blood, resulting in diabetes and ketonuria, abnormalities in water and electrolyte metabolism, blood concentration due to loss of electrolyte chambers, circulatory disorders, It can lead to pathological conditions such as kidney failure. Insulin is secreted from the β-cells of the pancreatic islets within the pancreas when the blood glucose concentration increases, and secretion is suppressed when the concentration of glucose in the blood decreases, thereby controlling the appropriate activity of energy sources. Diagnosis of diabetes is generally possible through measurement of blood glucose concentration. In humans, diabetes is generally diagnosed when blood glucose is above 200 mg/dl on a regular basis and above 140 mg/dl when fasting. Therefore, it can be usefully used in the treatment or prevention of diabetes by restoring damaged pancreatic β-cells or increasing glucose absorption in pancreatic islet cells.
본 발명에 있어서, 상기 당뇨병은 제1형 당뇨병 또는 제2형 당뇨병일 수 있으며, 용어 "당뇨병" 또는 "당뇨"는 혼용하여 사용될 수 있다.In the present invention, the diabetes may be type 1 diabetes or type 2 diabetes, and the terms “diabetes” or “diabetes” may be used interchangeably.
본 발명의 구체적인 일 실시예에서는, 속속이풀 추출물을 당뇨 제브라피쉬에 처리한 경우, 췌장섬 크기의 증가 효과를 확인한 바 (실시예 2), 속속이풀 추출물이 당뇨병의 개선에 효과가 있음을 확인하였다.In a specific example of the present invention, when treating diabetic zebrafish with the extract of Siberia chinensis, the effect of increasing the size of pancreatic islets was confirmed (Example 2), and it was confirmed that the extract of Sulfuria vulgaris is effective in improving diabetes. Confirmed.
본 발명의 용어 "예방"이란, 상기 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 조성물을 이용하여 당뇨병의 발생을 억제 또는 지연시키는 모든 행위를 말한다.The term "prevention" of the present invention refers to all actions that suppress or delay the occurrence of diabetes using a composition containing the above-mentioned extract or fraction thereof as an active ingredient.
본 발명의 용어 "치료"란, 상기 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 조성물을 이용하여 당뇨병의 증상을 다스리거나 낫게 하는 모든 행위를 말한다.The term "treatment" of the present invention refers to any action that treats or improves the symptoms of diabetes using a composition containing the extract or fraction thereof as an active ingredient.
본 발명의 "약학적 조성물"은 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 이러한 약학적으로 허용되는 담체, 부형제, 또는 희석제는 비자연적으로 발생된 것일 수 있다. 구체적으로, 상기 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 액제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The “pharmaceutical composition” of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent. These pharmaceutically acceptable carriers, excipients, or diluents may be non-naturally occurring. Specifically, the composition is formulated in the form of oral dosage forms such as powders, granules, tablets, solutions, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. can be used In the present invention, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium phosphate. , calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract and its fractions with at least one excipient, such as starch, calcium carbonate, It is prepared by mixing sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, and syrups, and may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives in addition to the commonly used simple diluents such as water and liquid paraffin. there is. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.
본 발명의 또 다른 하나의 양태는 상기 약학적 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 당뇨병의 치료 방법을 제공한다.Another aspect of the present invention provides a method of treating diabetes, comprising administering the pharmaceutical composition to a subject in need thereof.
상기 "약학적 조성물", "당뇨병", 및 "치료"는 전술한 바와 같다.The terms “pharmaceutical composition”, “diabetes”, and “treatment” are as defined above.
본 발명의 용어 "개체"란, 당뇨병이 발병되었거나 발병할 가능성이 있는 인간을 포함한 모든 동물을 의미할 수 있다. 상기 동물은 인간뿐만 아니라 이와 유사한 증상의 치료를 필요로 하는 소, 말, 양, 돼지, 염소, 낙타, 영양, 개, 고양이 등의 포유동물일 수 있으나, 이에 제한되지는 않는다. 본 발명의 조성물을 필요로 하는 개체는 인간이거나, 또는 인간을 제외한 개체일 수 있으나, 이에 제한되지 않는다.The term “individual” in the present invention may refer to any animal, including humans, that has developed or is likely to develop diabetes. The animal may be not only a human, but also a mammal such as a cow, horse, sheep, pig, goat, camel, antelope, dog, or cat that requires treatment for similar symptoms, but is not limited thereto. The subject in need of the composition of the present invention may be a human or a non-human subject, but is not limited thereto.
본 발명의 상기 예방 또는 치료 방법은 구체적으로, 당뇨병이 발병하였거나 발병할 위험이 있는 개체에 상기 조성물을 약학적으로 유효한 양으로 투여하는 단계를 포함할 수 있다.The prevention or treatment method of the present invention may specifically include administering the composition in a pharmaceutically effective amount to an individual who has developed or is at risk of developing diabetes.
본 발명에서 사용된 용어, "투여"는 어떠한 적절한 방법으로 환자에게 본 발 명의 약학적 조성물을 도입하는 것을 의미하며, 본 발명의 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 구체적으로, 경구 투여의 방법일 수 있으나, 이에 제한되지 않는다.As used in the present invention, the term "administration" means introducing the pharmaceutical composition of the present invention into a patient by any appropriate method, and the route of administration of the composition of the present invention is oral or parenteral as long as it can reach the target tissue. It can be administered through various routes. Specifically, it may be a method of oral administration, but is not limited thereto.
본 발명의 약학적 조성물의 유효성분은 투여받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 수 있다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 본 발명의 조성물의 투여 빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The active ingredient of the pharmaceutical composition of the present invention may vary depending on the age, gender, weight, pathological condition and severity of the subject to be administered, route of administration, or the judgment of the prescriber. Determination of the application amount based on these factors is within the level of those skilled in the art, and the frequency of administration of the composition of the present invention is not particularly limited, but may be administered once a day or divided doses and administered several times. The above dosage does not limit the scope of the present invention in any way.
본 발명의 또 다른 하나의 양태는 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 개선용 식품 조성물을 제공한다.Another aspect of the present invention provides a food composition for preventing or ameliorating diabetes, comprising an extract or a fraction thereof as an active ingredient.
본 발명의 또 다른 하나의 양태는 속속이풀 추출물 또는 이의 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 개선용 건강기능식품 조성물을 제공한다.Another aspect of the present invention provides a health functional food composition for preventing or improving diabetes, comprising an extract or a fraction thereof as an active ingredient.
상기 "속속이풀 추출물 또는 이의 분획물", "당뇨병" 및 "예방"은 전술한 바와 같다.The terms “Helloweed extract or fraction thereof,” “diabetes,” and “prevention” are the same as described above.
본 발명의 용어 "개선"은 상기 조성물을 이용하여 질환 의심 및 발병 개체의 증상이 호전되거나 이롭게 되는 모든 행위를 의미한다.The term “improvement” of the present invention refers to any action that improves or benefits the symptoms of an individual suspected of having a disease or is affected by using the composition.
본 발명의 용어 "식품"은 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료, 비타민 복합체, 건강기능식품 등의 통상적인 의미의 식품을 모두 포함하며, 본 발명의 속속이풀 추출물 또는 이의 분획물을 포함할 수 있는 한, 이에 제한되지 않는다. 또한 본 발명에 따른 속속이풀 추출물 또는 이의 분획물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있으며, 환제, 분말, 과립, 침제, 정제, 캡슐 또는 액제 등의 형태를 포함할 수 있다.The term "food" in the present invention refers to meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, It includes all foods in the conventional sense, such as vitamin complexes and health functional foods, and is not limited thereto, as long as it can include the extract or fractions thereof of the present invention. In addition, it can be manufactured by adding the extract or fraction thereof according to the present invention to juices, teas, jellies and juices prepared as main ingredients, and can be prepared in the form of pills, powders, granules, steeps, tablets, capsules or liquids. It can be included.
상기 식품 조성물의 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있으며, 그 종류는 특별히 제한되지 않는다. 예를 들어, 통상의 식품과 같이 여러 생약 추출물, 식품학적으로 허용 가능한 식품보조첨가제 또는 천연 탄수화물 등을 추가 성분으로 포함할 수 있으며, 이에 제한되지 않는다. 유효성분의 혼합양은 사용 목적에 따라 적합하게 결정될 수 있으며, 본 발명의 조성물은 천연물로부터 유래한 추출물을 유효성분으로 하므로, 안전성 면에서 문제가 없기 때문에 혼합량에 큰 제한은 없다.When manufacturing the food composition, it can be manufactured by adding raw materials and ingredients commonly added in the art, and the types are not particularly limited. For example, like regular foods, it may include various herbal extracts, foodologically acceptable food additives, or natural carbohydrates as additional ingredients, but is not limited thereto. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use, and since the composition of the present invention uses extract derived from natural products as the active ingredient, there is no problem in terms of safety, so there is no significant limitation on the mixing amount.
본 발명의 용어 "건강기능식품"은 특정보건용 식품(food for special health use, FoSHU)과 동일한 용어로, 건강보조의 목적으로 특정 성분을 원료로 하거나 식품 원료에 들어있는 특정 성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말한다. 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 상기 건강기능식품용 조성물은 질병의 예방 및 질병의 회복 등과 관련된 기능을 수행할 수 있다. 본 발명의 건강기능식품은 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다.The term "health functional food" in the present invention is the same as food for special health use (FoSHU), and is made of specific ingredients as raw materials or extracts and concentrates specific ingredients contained in food raw materials for the purpose of health supplementation. Refers to food manufactured and processed through methods such as refining, mixing, etc. It refers to a food designed and processed so that the above ingredients can sufficiently exert bioregulatory functions such as biodefense, regulation of biorhythm, prevention and recovery of disease, etc. to the living body. The composition for health functional food is used to prevent and prevent diseases. It can perform functions related to recovery, etc. The health functional food of the present invention can be used interchangeably with terms known in the art, such as functional food.
본 발명의 또 다른 하나의 양태는 속속이풀 추출물 또는 이의 분획물 또는 이를 포함하는 조성물의 당뇨병의 예방 또는 치료 용도를 제공한다. Another aspect of the present invention provides the use of an extract or fraction thereof or a composition containing the same for the prevention or treatment of diabetes.
본 발명의 또 다른 하나의 양태는 속속이풀 추출물 또는 이의 분획물 또는 이를 포함하는 조성물의 당뇨병 예방 또는 치료를 위한 약제를 제조하기 위한 용도를 제공한다.Another aspect of the present invention provides the use of an extract or fraction thereof or a composition containing the same for preparing a medicine for preventing or treating diabetes.
상기 "속속이풀 추출물 또는 이의 분획물", "당뇨병" 및 "예방"은 전술한 바와 같다.The terms “Helloweed extract or fraction thereof,” “diabetes,” and “prevention” are the same as described above.
본 발명의 속속이풀 추출물 또는 이의 분획물을 포함하는 조성물은 고혈당 또는 당뇨병의 주요 증상을 감소시키면서도 경구 투여가 가능한 바, 당뇨병의 예방 또는 치료에 널리 활용될 수 있을 것이다.The composition containing the extract or fractions thereof of the present invention can be administered orally while reducing the main symptoms of hyperglycemia or diabetes, so it can be widely used in the prevention or treatment of diabetes.
도 1은 당뇨 제브라피쉬에 속속이풀 추출물을 처리한 결과를 나타내는 형광현미경 사진 및 상기 형광현미경 사진으로부터 산출된 췌장섬의 크기 변화를 나타내는 그래프이다.Figure 1 is a fluorescence microscopic image showing the results of treating diabetic zebrafish with a P. vulgaris extract and a graph showing changes in the size of pancreatic islets calculated from the fluorescence microscopy image.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples.
실시예 1. 속속이풀 추출물의 제조Example 1. Preparation of Extract of P. vulgaris
본 발명의 속속이풀(Rorippa palustris (L.) Besser)은 국립낙동강생물자원관 생물자원은행에서 분양 받아 사용하였다 (2017001N065). 속속이풀의 지상부를 70% 에탄올로 추출하여 본 발명의 속속이풀 추출물을 제조하였다. Rorippa palustris (L.) Besser) of the present invention was purchased and used from the National Nakdong River Biological Resources Center Biological Resource Bank (2017001N065). The above-ground part of the plant was extracted with 70% ethanol to prepare the plant extract of the present invention.
실시예 2. 과다 인슐린 유래 당뇨 증상에 대한 속속이풀 추출물의 효과Example 2. Effect of Extract of Euphorbiaceae on Excessive Insulin-induced Diabetes Symptoms
과다한 인슐린으로 유발한 당뇨 제브라피쉬를 대상으로, 속속이풀 추출물의 항당뇨 효과를 시험하였다.The anti-diabetic effect of the extract of Euphorbia fernata was tested in zebrafish with diabetes induced by excessive insulin.
구체적으로, 수정 3일 후(3 day post fertilization)의 제브라피쉬 유생(zebrafish larvae)을 6-well에 위치시킨 후, 10μM 인슐린에 48시간 동안 노출시켰다. 0.03% 해수염 용액에 24시간 노출 시킨 후, 속속이풀 추출물 1μg/mL를 24시간 동안 처리하였다. 직접적인 췌장섬의 관찰을 위해 형광현미경(Olympus 1×70, Olympus, Japan)을 사용하였으며, 형광현미경 관찰 전에 40μM 2-NBDG로 30분 동안 염색하였다. 형광현미경을 통해 획득한 이미지는 Focus Lite 소프트웨어를 사용하여 제브라피쉬의 췌장섬 크기를 분석하였다. Specifically, zebrafish larvae 3 days post fertilization were placed in a 6-well and exposed to 10 μM insulin for 48 hours. After exposure to 0.03% sea salt solution for 24 hours, 1 μg/mL of P. fern extract was treated for 24 hours. A fluorescence microscope (Olympus 1×70, Olympus, Japan) was used to directly observe pancreatic islets, and they were stained with 40 μM 2-NBDG for 30 minutes before observation under a fluorescence microscope. Images acquired through a fluorescence microscope were used to analyze the size of zebrafish pancreatic islets using Focus Lite software.
분석 결과, 속속이풀 추출물 처리군의 췌장섬 크기가 미처리 대조군에 비해 유의적으로 증가한 것으로 나타났다 (도 1). 이로써, 속속이풀 추출물의 항당뇨 효능을 확인하였다.As a result of the analysis, it was found that the size of the pancreatic islets in the group treated with the herbacea extract was significantly increased compared to the untreated control group (Figure 1). As a result, the anti-diabetic effect of the extract of Siberia chinensis was confirmed.
[제제예][jejeye]
속속이풀 추출물을 사용하여 아래와 같은 제형을 제조하였다. 그러나, 하기 제제예는 본 발명을 예시하는 것일 뿐, 이에 의해 본 발명의 내용이 제한되는 것은 아니다.The following formulation was prepared using the extract of P. chinensis. However, the following formulation examples only illustrate the present invention and do not limit the content of the present invention.
제제예 1. 정제의 제조Formulation Example 1. Preparation of tablets
속속이풀 추출물 200 ㎎200 ㎎ of P. chinensis extract
유당 100 ㎎Lactose 100 mg
전분 100 ㎎Starch 100 mg
스테아린산 마그네슘 적량Magnesium stearate dosage
통상의 정제 제조방법에 따라 상기의 성분을 혼합하고 타정하여 정제를 제조하였다Tablets were prepared by mixing the above ingredients and compressing them according to a typical tablet manufacturing method.
제제예 2. 액제의 제조Formulation Example 2. Preparation of liquid formulation
속속이풀 추출물 1000 ㎎Extract 1000 mg
CMC-Na 20 g20 g of CMC-Na
이성화당 20 g20 g isomerized sugar
레몬향 적량Lemon flavor appropriate amount
정제수를 가하여 전체 1000 ㎖로 맞추었다. 통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 갈색병에 충전하고 멸균시켜 액제를 제조하였다.Purified water was added to bring the total volume to 1000 ml. The above ingredients were mixed according to a typical liquid preparation method, then filled into a brown bottle and sterilized to prepare a liquid.
제제예 3. 캡슐제의 제조Formulation Example 3. Preparation of capsules
속속이풀 추출물 300 ㎎300 ㎎ of P. chinensis extract
결정성 셀룰로오스 3 ㎎Crystalline cellulose 3 mg
락토오스 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 0.2 ㎎Magnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.Capsules were prepared by mixing the above ingredients and filling them into gelatin capsules according to a typical capsule manufacturing method.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
속속이풀 추출물 300 ㎎Peach extract 300 mg
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎Sterile distilled water for injection 2974 mg
Na2HPO412H2O 26 ㎎Na 2 HPO 4 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ㎖) 상기의 성분 함량으로 제조하였다. It was prepared with the above ingredients per ampoule (2 ml) according to the usual manufacturing method for injections.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concepts thereof.
Claims (6)
상기 당뇨병은 제1형 당뇨병 또는 제2형 당뇨병인 것인, 약학적 조성물.
A pharmaceutical composition for the prevention or treatment of diabetes containing an extract or a fraction thereof as an active ingredient,
A pharmaceutical composition, wherein the diabetes is type 1 diabetes or type 2 diabetes.
The pharmaceutical composition according to claim 1, wherein the extract is prepared by extraction with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
A method of treating diabetes, comprising administering the composition of claim 1 or 2 to an entity other than a human.
A food composition for preventing or ameliorating diabetes, comprising an extract or a fraction thereof as an active ingredient.
A health functional food composition for preventing or improving diabetes, comprising an extract or a fraction thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210026764A KR102613901B1 (en) | 2021-02-26 | 2021-02-26 | Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210026764A KR102613901B1 (en) | 2021-02-26 | 2021-02-26 | Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220122301A KR20220122301A (en) | 2022-09-02 |
KR102613901B1 true KR102613901B1 (en) | 2023-12-14 |
Family
ID=83280890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210026764A KR102613901B1 (en) | 2021-02-26 | 2021-02-26 | Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102613901B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101989739B1 (en) * | 2018-02-21 | 2019-06-14 | 경희대학교 산학협력단 | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts |
-
2021
- 2021-02-26 KR KR1020210026764A patent/KR102613901B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101989739B1 (en) * | 2018-02-21 | 2019-06-14 | 경희대학교 산학협력단 | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts |
Also Published As
Publication number | Publication date |
---|---|
KR20220122301A (en) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
KR20190132420A (en) | Herbal composition | |
KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
JP7303582B2 (en) | A composition for prevention, amelioration and treatment of metabolic syndrome associated with obesity and/or diabetes, containing a compound of an Indian gooseberry extract and a young barley leaf extract (IB compound) as an active ingredient | |
CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR101246689B1 (en) | Antidiabetic composition comprising plants extract mixture | |
KR102613901B1 (en) | Composition for preventing or treating diabetes comprising extract of Rorippa palustris or a fraction thereof | |
KR102599594B1 (en) | Composition for preventing or treating diabetes comprising extract of Carex miyabei or a fraction thereof | |
KR102655708B1 (en) | Composition for preventing or treating diabetes comprising extract of Juncus effusus or a fraction thereof | |
KR102453757B1 (en) | Composition for preventing or treating diabetes comprising extract of Cardamine flexuosa or a fraction thereof | |
KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
KR101303541B1 (en) | A composition having effects of preventing alcoholic liver damage and alcoholic fat liver and of ameliorating hangover | |
KR101719709B1 (en) | Composition for preventing or treating metabolic disorders comprising extracts of Lonicera japonica Thunb. and Rehmannia glutinosa Liboch | |
KR20220122299A (en) | Composition for preventing or treating diabetes comprising extract of Rumex crispus or a fraction thereof | |
KR20220122298A (en) | Composition for preventing or treating diabetes comprising extract of Juncus effusus or a fraction thereof | |
KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
KR20050003665A (en) | Composition comprising an extract of Peucedanum japonicum for preventing and treating diabetes | |
Tuem et al. | Effect of aqueous and methanolic extracts of Solanum aethiopicum Linn Gilo (Solanaceae) leaves on body weight and Glycemia in rats with alloxan-induced diabetes | |
KR101278706B1 (en) | Compositions and functional food for prevention or treatment of diabetic complications comprising using extract of Hedera rhombea | |
KR102172371B1 (en) | A pharmaceutical composition comprising extract of Aloe, quince and corn silk for preventing or treating obesity | |
KR20090003661A (en) | Functional drink comprising extracts of commelina communis and eleutherococcus for antidiabetic mellitus activity and prevention and the manufacturing method thereof | |
KR102137147B1 (en) | Compositions for preventing or treating diabetes comprising Benzyl α-D-galactopyranoside or (-)-secoisolariciresinol-9'-O-β-D-glucopyranoside | |
KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |